(Reuters) – The U.S. Food and Drug Administration website showed that most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
Comments